Iph4102-201
Web29 jan. 2024 · Innate Pharma : RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME MarketScreener INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME Fast Track designation is … Web12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der …
Iph4102-201
Did you know?
Web29 nov. 2024 · Aims: Sezary Syndrome (SS) is the most aggressive form of cutaneous T cell lymphoma (CTCL), characterized with high blood involvement and expression o… WebBrief Title: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Official Title: TELLOMAK: T-cell Lymphoma Anti- KIR3DL2 Therapy . …
Web12 jun. 2024 · IPH4102 is a humanized first-in-class anti-KIR3DL2 monoclonal antibody designed to deplete KIR3DL2-expressing cells via antibody-dependent cell-cytotoxicity (ADCC) and phagocytosis. Web12 apr. 2024 · Protocol: IPH4102-201: TELLOMAK: An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with …
WebRELATED APPLICATIONS. This application claims priority to U.S. Provisional Application No. 63/221,595 filed on Jul. 14, 2024, the content of which is hereby incorporated in its en Web1 aug. 2024 · IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form, Sézary syndrome. We aimed to assess the safety and activity of IPH4102 in cutaneous T-cell lymphoma. Methods
WebArms in the two indications will consist of two cohorts each and will investigate IPH4102 in KIR3DL2 expressing and non-expressing patients. The trial’s primary endpoint is objective response rate and key secondary measures include treatment emergent adverse events, quality of life, overall response rate, progression-free survival, and overall survival.
Web7 jun. 2024 · IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody that depletes KIR3DL2-expressing cells through antibody-dependent cell-cytotoxicity and … on what day of creation did god create manWeb29 okt. 2015 · IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2024 Aug;20 (8):1160-1170. doi: 10.1016/S1470-2045 (19)30320-1. Epub 2024 Jun 25. Study record dates on what day is the passover lamb sacrificedWebIPH4102 alleen of in combinatie met chemotherapie bij patiënten met gevorderd T-cellymfoom TELLOMAK: T-cellymfoom Anti-KIR3DL2-therapie. Een open label, … iot sensors predictive maintenance monitorWeb3 dec. 2024 · innate pharma announces updated results that support advancement of iph4102 in refractory sÉzary syndrome at the american society of hematology 2024 annual meeting differentiating... march 26, 2024 on what day is the veinticincoWebInnate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the design of the “TELLOMAK” Phase II trial and new preclinical data supporting the potential of IPH4102 in peripheral T-cell lymphoma (“PTCL”) as well as Adult T-cell leukemia/lymphoma (“ATLL”) will be presented at the International Conference on … on what day of the week do chickens hideWebInterpretation IPH4102 is safe and shows encouraging clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome. If confirmed in future trials, IPH4102 could become a novel treatment option for these patients. A multi-cohort, phase 2 trial (TELLOMAK) is underway to confirm on what day was aamu foundedWeb15 jun. 2024 · IPH4102 is Innate Pharma’s wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells. 25 patients, with a median age of 71 years old and a median number of four prior systemic treatments, were evaluable for safety (10 dose levels: 0.0001 to 10 mg/kg). on what day do you ovulate